AOD-9604 has no FDA-approved dose because it has no FDA-approved indication. Everything in the practitioner space is built on a mix of preclinical pharmacology, the Phase 2 oral trial data from Metabolic Pharmaceuticals, and clinical experience accumulated through compounding pharmacies and peptide-focused practices. The protocols below reflect what is widely used, not what is rigorously validated.<\/p>\n
What follows is a practical layout of subcutaneous AOD-9604 dosing, cycling considerations, injection technique, and the labs and outcome markers worth tracking. If a clinician offers a dose much higher than the ranges here, push back and ask for the rationale.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
The most common subcutaneous dose used in peptide practice is 300 mcg once daily.<\/strong> This is the dose that emerged from translation of the rodent lipolysis data and from observational practitioner experience after the oral trial program ended. Some protocols start lower at 250 mcg and titrate up. Others run 500 mcg in the first cycle and step down for maintenance.<\/p>\n Quick Answer: Standard subcutaneous protocol is 300 mcg once daily, usually morning and fasted<\/p>\n Oral doses in the Metabolic Pharmaceuticals Phase 2 trials went from 1 mg to 25 mg per day because oral bioavailability is poor. Those numbers should not be back-converted to subcutaneous doses. The injected route is far more efficient on a milligram basis, and the published oral doses are not a relevant benchmark for what to inject.<\/p>\n If a clinician proposes 1 mg daily subcutaneous, that is a high dose with no published safety data behind it. The peptide is well tolerated in trials at the levels tested, but pushing the dose 3-4x without monitoring is reasonable only with explicit informed consent and frequent labs.<\/p>\n Most protocols dose AOD-9604 in the morning, fasted, before any meals or training.<\/strong> The reasoning is that low circulating insulin amplifies lipolysis. Insulin suppresses hormone-sensitive lipase and pushes fat cells into storage mode. Dosing the peptide when insulin is low theoretically lets the lipolytic signal have a bigger effect.<\/p>\n Some practitioners split the daily dose, 150 mcg in the morning fasted and 150 mcg pre-dinner. The case for splitting is the short half-life. By the time you reach the evening, the morning dose has cleared. A split protocol keeps drug exposure more consistent. The downside is two daily injections instead of one.<\/p>\n A third pattern is pre-cardio dosing, with the full dose 30-60 minutes before fasted aerobic exercise. This compounds the peptide effect on the lipolytic stimulus that exercise itself produces. There is no head-to-head trial of these timing strategies, so the choice is empirical.<\/p>\n AOD-9604 is given as a subcutaneous injection using an insulin syringe, typically a 0.3 mL or 0.5 mL syringe with a 29-31 gauge needle.<\/strong> Common injection sites are the abdomen (at least 2 inches from the navel), the front or outer thigh, or the back of the upper arm. Rotate sites to avoid lipodystrophy.<\/p>\n Reconstitution is a step worth getting right. A 5 mg vial of lyophilized peptide is typically reconstituted with 2 mL of bacteriostatic water, giving a concentration of 2.5 mg\/mL or 2500 mcg\/mL. At that concentration, 300 mcg is 0.12 mL on the syringe. Different vial sizes or fill volumes change this math. The compounding pharmacy should provide explicit reconstitution and dosing instructions for the specific vial.<\/p>\n Once reconstituted, AOD-9604 is stored refrigerated and used within 28 days or per the pharmacy’s stability data. Bring the vial to room temperature before injection. Clean the rubber stopper with alcohol. Draw the dose without introducing air bubbles. Clean the injection site, pinch the skin, insert at 90 degrees for abdominal sites, and inject slowly. Withdraw and apply gentle pressure.<\/p>\n Most practitioners run 8-12 week cycles followed by a 4 week break.<\/strong> The rationale is partly to avoid receptor desensitization and partly to keep cumulative exposure conservative given the limited long-term human data. Within a cycle, dosing is usually daily 5 or 7 days per week.<\/p>\n A common structure looks like this. Weeks 1-4 at 300 mcg daily morning fasted. Weeks 5-8 same dose, continue tracking body composition and lipids. Weeks 9-12 same dose. Take 4 weeks off. If the first cycle produced measurable change, start a second cycle. If not, the molecule is probably not doing meaningful work for that individual and continuing is unlikely to help.<\/p>\n Some practitioners do 5 days on, 2 days off within each week. The pharmacology rationale is weak for this pattern given the short half-life, but it is a real protocol in use.<\/p>\n AOD-9604 does not produce the gastrointestinal side effects that drive the slow titration schedule for GLP-1 drugs like semaglutide and tirzepatide.<\/strong> There is no clinical need to titrate from a tolerability perspective. Most people can start at the full dose without issue.<\/p>\n The argument for starting at 250 mcg and stepping up to 300 mcg in week 2 is mostly psychological and habit-formation focused. It lets a person get used to daily subcutaneous injection technique without immediately committing to the higher dose. For most people, starting at 300 mcg from day 1 is fine.<\/p>\n If a person is sensitive to injection site reactions or has any unexpected response, dropping back to 150 mcg for a few days is reasonable.<\/p>\n Baseline labs at the start of a cycle should include fasting glucose, HbA1c, fasting insulin (if available), IGF-1, complete metabolic panel, lipid panel, and TSH with free T4.<\/strong> These create a snapshot of metabolic and endocrine baseline.<\/p>\n Repeat at week 12 or at the end of the cycle. Important comparisons are IGF-1 stability (should not rise), fasting glucose stability (should not worsen), and lipid panel direction (HDL and triglycerides may improve with active lipolysis). DEXA body composition at baseline and end-of-cycle is the gold standard for measuring fat versus lean mass change.<\/p>\n If IGF-1 rises significantly, the product may be contaminated or mislabeled. AOD-9604 should not affect IGF-1 if it is what it claims to be. This is a useful quality check.<\/p>\n Key Takeaway: Track DEXA body composition or waist circumference at baseline and 12 weeks<\/p>\n Realistic expectations on AOD-9604 alone are modest.<\/strong> The largest human trial (Ng et al. 2008 Obesity) did not show statistically significant weight loss versus placebo over 24 weeks of oral dosing. Subcutaneous protocols do not have published trial data of the same scale. Practitioner observation suggests 1-3% body fat reduction over 12 weeks is on the higher end of what people report.<\/p>\n If you are also on semaglutide or tirzepatide, the GLP-1 induced weight loss will dominate the signal. STEP 1 showed 14.9% weight loss with semaglutide at 68 weeks. SURMOUNT-1 showed 20.9% with tirzepatide at 72 weeks. AOD-9604 added on top, if it adds anything, would shift the composition of that loss slightly toward more fat and less lean mass. The total weight loss number will look like the GLP-1 number, not a separate AOD effect.<\/p>\n If after 12 weeks of consistent dosing your DEXA shows no measurable change in fat mass and no change in lipids, the molecule is not doing measurable work for you. Continuing is unlikely to change that.<\/p>\n In practitioner protocols AOD-9604 is often paired with growth hormone secretagogues like ipamorelin or CJC-1295.<\/strong> The logic is layered. AOD-9604 acts peripherally on the fat cell. Ipamorelin and CJC-1295 stimulate endogenous growth hormone release through GHRH and ghrelin receptor pathways. The combination theoretically gives a peripheral lipolytic signal plus a central anabolic signal that may preserve lean mass.<\/p>\n Combination is not validated in randomized trials. The published data on each peptide individually is preclinical and small-scale. Stacking adds cost, complexity and unknown interactions. If you are going to combine, work with a peptide-experienced clinician who can monitor labs carefully.<\/p>\n AOD-9604 plus GLP-1 medication is a different combination. GLP-1 drugs reduce caloric intake centrally; AOD-9604 increases lipolysis peripherally. The combination is conceptually compatible. TrimRx provides GLP-1 medications as the foundation of weight management therapy.<\/p>\n The sourcing question is non-trivial.<\/strong> AOD-9604 sold by online research peptide vendors as “not for human use” is unregulated, often poorly purified and may not even be the labeled molecule. Independent testing of research-grade peptide vials regularly finds contaminants, wrong sequences or below-label content.<\/p>\n Compounded AOD-9604 from a licensed 503A or 503B pharmacy is a much better option. The pharmacy uses USP-grade raw material with certificates of analysis, follows USP-797 sterile compounding standards, and works under prescription from a licensed clinician. The cost is higher but the quality assurance is real.<\/p>\n If your only access is through a research peptide vendor, the safety and authenticity of the product cannot be verified. That is a significant risk to take for a peptide with limited efficacy data to begin with.<\/p>\n AOD-9604 has not been studied in pregnancy or breastfeeding and should not be used in those contexts.<\/strong> People with active cancer should avoid all growth-related peptides as a precaution, even though AOD-9604 does not raise IGF-1. People with uncontrolled diabetes, untreated thyroid disease, recent cardiac events or untreated pituitary disease should not start the peptide without specialist input.<\/p>\n People taking other weight management medications, including GLP-1 drugs from TrimRx or another provider, should let the prescribing clinician know about any adjunct peptides. Drug interactions are not well characterized but transparency is the right baseline.<\/p>\n Bottom line: Source matters: 503A or 503B compounded product only, not research-grade vials<\/p>\n There is no human data on continuous use beyond about 24 weeks. Cycling 8-12 weeks on and 4 weeks off is the conservative approach. The molecule is well tolerated in the published trials, so theoretical safety risks of continuous use are low, but the safety database is shallow.<\/p>\n Morning fasted is the most common timing because low circulating insulin amplifies lipolysis. Pre-cardio dosing is a reasonable alternative if exercise is part of your routine. Evening dosing is fine if morning does not fit your schedule.<\/p>\n Most compounded vials are 2 mg or 5 mg of lyophilized peptide. After reconstitution with 2 mL of bacteriostatic water, a 5 mg vial holds 2500 mcg\/mL. At 300 mcg per day, a 5 mg vial lasts about 16 days. Vial size and concentration vary by pharmacy, so follow the pharmacy’s specific instructions.<\/p>\n Yes for practical purposes. Oral absorption is poor and the doses used in oral trials did not produce clinically meaningful weight loss. Subcutaneous injection is the route used in current peptide practice. There is no FDA-approved oral or sublingual product.<\/p>\n Stop subcutaneous injections at least 24-48 hours before any planned surgery. The half-life is short, so a few days of washout is more than enough to clear the molecule. Tell your surgical team about any peptide use as part of full medication disclosure.<\/p>\n AOD-9604 is on the WADA prohibited list for competitive athletes. Standard non-athletic urine drug screens (employment or recreational) do not test for it. Athletes in WADA-tested sports should not use the peptide.<\/p>\n Take the missed dose when you remember if it is the same day. If you remember the next morning, skip the missed dose and resume the normal schedule. Do not double up. With a half-life under an hour and once-daily dosing, missing one dose is not metabolically significant.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n <\/p>\n AOD-9604 has no FDA-approved dose because it has no FDA-approved indication.<\/p>\n","protected":false},"author":11,"featured_media":92591,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"AOD-9604 Dosing Protocol: Cycling, Frequency & Best Practices","_yoast_wpseo_metadesc":"AOD-9604 has no FDA-approved dose because it has no FDA-approved indication.","_yoast_wpseo_focuskw":"aod 9604 dosing","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[19],"tags":[25,40],"class_list":["post-89125","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-longevity","tag-dosing","tag-peptides"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=89125"}],"version-history":[{"count":4,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89125\/revisions"}],"predecessor-version":[{"id":93592,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89125\/revisions\/93592"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/92591"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=89125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=89125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=89125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}When Should You Take AOD-9604?<\/h2>\n
How Is the Peptide Injected?<\/h2>\n
What Is a Typical Cycle?<\/h2>\n
Do You Need to Titrate the Dose?<\/h2>\n
What Labs Should You Check?<\/h2>\n
What Body Composition Changes Can You Expect?<\/h2>\n
Can You Combine AOD-9604 with Other Peptides?<\/h2>\n
Where Should You Source AOD-9604?<\/h2>\n
What About Pregnancy, Breastfeeding and Chronic Conditions?<\/h2>\n
FAQ<\/h2>\n
Can You Take AOD-9604 Every Day Forever?<\/h3>\n
What Time of Day Is Best for AOD-9604?<\/h3>\n
How Much AOD-9604 in a Vial?<\/h3>\n
Do You Have to Inject AOD-9604?<\/h3>\n
Should You Stop AOD-9604 Before Surgery?<\/h3>\n
Can AOD-9604 Fail a Drug Test?<\/h3>\n
What If You Miss a Dose?<\/h3>\n
Related Articles<\/h2>\n
\n